Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Rectal TAF/EVG Inserts (RITE PrEP)
NCT06274398Phase 1Completed
- Sponsor
- Eastern Virginia Medical School
- Start
- Jan 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tenofovir alafenamide and elvitegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Eastern Virginia Medical School. Primary endpoints: Frequency and intensity of Adverse Events at Day 57, Pharmacokinetics (Cmax) in blood at 72 hours and 2 more. Started Jan 2024; status: completed.
02
Drugs
tenofovir alafenamideelvitegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06274398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06274398.